Montreux, Switzerland | April 4, 2023 – MedXCell SA, a European venture builder that specializes in cell therapy for major diseases such as cancer, autoimmune, neurological, and degenerative diseases, is pleased to announce that its paper “Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody” has been published in the International Journal of Pharmaceutics and is now accessible online here.
Using the best candidate functional excipient, MedXCell was able to demonstrate successful delivery of a SARS-CoV-2 neutralizing monoclonal antibody into the entirety of the respiratory tract of experimental mice, with concomitant prophylactic and post-exposure protection from SARS-CoV-2 pathology.
MedXCell identifies or initiates commercially viable research projects with academic institutions and
develops and supports them through a co-design phase, which can help to drastically reduce project
risks before the creation of the start-up. Based on the outcome of this phase, MedXCell creates a new
entity that is well-prepared for independent financing or establishes an early strategic partnership.
For more information, please contact: